XML 36 R25.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2018

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule of intangible assets

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2018 and December 31, 2017:

		March 31, 2018
		Gross Carrying Amount				Accumulated Amortization				Net Amount				Weighted- Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
OPERA^®software patent		$	31,951			$	(8,986	)		$	22,965				11.50
Development costs of corporate website			91,743				(91,743	)			—				n/a
Approved hormone therapy drug candidate patents			1,413,755				(192,609	)			1,221,146				14.75
Hormone therapy drug candidate patents (pending)			1,738,417				—				1,738,417				n/a
Non-amortizable intangible assets:
Multiple trademarks			238,158				—				238,158				indefinite
Total		$	3,514,024			$	(293,338	)		$	3,220,686

		December 31, 2017
		Gross Carrying Amount				Accumulated Amortization				Net Amount				Weighted- Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
OPERA^®software patent		$	31,951			$	(8,487	)		$	23,464				11.75
Development costs of corporate website			91,743				(91,743	)			—				n/a
Approved hormone therapy drug candidate patents			1,293,614				(171,911	)			1,121,703				15
Hormone therapy drug candidate patents (pending)			1,721,305				—				1,721,305				n/a
Non-amortizable intangible assets:
Multiple trademarks			233,275				—				233,275				indefinite
Total		$	3,371,888			$	(272,141	)		$	3,099,747

Schedule of estimated amortization expense

Estimated amortization expense for the next five years for the patent cost currently being amortized is as follows:

Year Ending December 31,				Estimated Amortization
	2018(9 months)			$	63,590
	2019			$	84,786
	2020			$	84,786
	2021			$	84,786
	2022			$	84,786
	Thereafter			$	841,377